References

Liberati A, Altman D, Tetzlaff J, Mulrow C, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):W65–W94. [PubMed: 19622512]

Wolfe F, Clauw DJ, Fitzcharles M-A, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res. 2010 May;62(5):600–610. [PubMed: 20461783]

Wolfe F. New American College of Rheumatology criteria for fibromyalgia: a twenty-year journey. Arthritis Care Res. 2010;62(5):583–584. [PubMed: 20461781]

Lawrence R, Felson D, Helmick C, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008;58(1):26–35. [PMC free article: PMC3266664] [PubMed: 18163497]

White KP, Speechley M, Harth M, Ostbye T. The London Fibromyalgia Epidemiology Study: the prevalence of fibromyalgia syndrome in London, Ontario. J Rheumatol. 1999;26:1570–1576. [PubMed: 10405947]

Weir P, Harlan G, Nkoy F, et al. The incidence of fibromyalgia and its associated comorbidities: a population-based retrospective cohort study based on International Classification of Diseases, 9th Revision codes. Journal of Clinical Rheumatology. 2006;12(3):124–128. [PubMed: 16755239]

Burgmer M, Pogatzki-Zahn E, Gaubitz M, Wessoleck E, Heuft G, Pfleiderer B. Altered brain activity during pain processing in fibromyalgia. Neuroimage. 2009;44(2):502–508. [PubMed: 18848998]

Staud R. Biology and therapy of fibromyalgia: pain in fibromyalgia syndrome. Arthritis Research & Therapy. 2006;8(3):208. [PMC free article: PMC1526632] [PubMed: 16684376]

Verdu B, Decosterd I, Buclin T, Stiefel F, Berney A. Antidepressants for the treatment of chronic pain. Drugs. 2008;68(18):2611–2632. [PubMed: 19093703]

Abeles AM, Pillinger MH, Solitar BM, Abeles M. Narrative review: the pathophysiology of fibromyalgia. Ann Intern Med. 2007 May 15;146(10):726–734. [PubMed: 17502633]

Arnold LM. The pathophysiology, diagnosis and treatment of fibromyalgia. Psychiatr Clin North Am. 2010 Jun;33(2):375–408. [PubMed: 20385343]

Clauw DJ. Fibromyalgia: An Overview. Am J Med. 2009;122(12):S3–S13. [PubMed: 19962494]

Burckhardt CS, Goldenberg D, Crofford L, et al. Guideline for the Management of Fibromyalgia Syndrome Pain in Adults and Children. APS Clinical Practice Guidelines Series. 2005:1–107.

Bennett RM, Clark SC, Walczyk J. A randomized, double-blind, placebo-controlled study of growth hormone in the treatment of fibromyalgia. Am J Med. 1998 Mar;104(3):227–231. [PubMed: 9552084]

Cuatrecasas G, Riudavets C, Guell MA, Nadal A. Growth hormone as concomitant treatment in severe fibromyalgia associated with low IGF-1 serum levels. A pilot study. BMC Musculoskeletal Disorders. 2007;8:119. [PMC free article: PMC2212629] [PubMed: 18053120]

Hannonen P, Malminiemi K, Yli-Kerttula U, Isomeri R, Roponen P. A randomized double-blind placebo controlled study of moclobemide and amitriptyline in fibromyalgia. Scand-J-Rheumatol. 1998;27(3):246. [PubMed: 9973149]

Yavuzer G, Kucukdeveci A, Arasil T, Elhan A. Moclobemid treatment in primary fibromyalgia syndrome. European Journal of Physical Medicine and Rehabilitation. 1998;8(2):35–38.

Skrabek RQ, Galimova L, Ethans K, Perry D. Nabilone for the treatment of pain in fibromyalgia. Journal of Pain. 2008 Feb;9(2):164–173. [PubMed: 17974490]

Ware MA, Fitzcharles M-A, Joseph L, Shir Y. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth Analg. 2010 Feb;110(2):604–610. [PubMed: 20007734]

Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Medicine. 2009 05-06;10(4):663–672. [PMC free article: PMC2891387] [PubMed: 19453963]

Sadreddini S, Molaeefard M, Noshad H, Ardalan M, Asadi A. Efficacy of Raloxifene in treatment of fibromyalgia in menopausal women. European Journal of Internal Medicine. 2008 Jul;19(5):350–355. [PubMed: 18549938]

Olin R, Klein R, Berg PA. A randomised double-blind 16-week study of ritanserin in fibromyalgia syndrome: clinical outcome and analysis of autoantibodies to serotonin, gangliosides and phospholipids. Clin Rheumatol. 1998;17(2):89–94. [PubMed: 9641502]

Russell IJ, Perkins AT, Michalek JE, Oxybate SXBFSSG. Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: a randomized, double-blind, placebo-controlled, multicenter clinical trial. Arthritis Rheum. 2009 Jan;60(1):299–309. [PubMed: 19116896]

Scharf MB, Baumann M, Berkowitz DV. The effects of sodium oxybate on clinical symptoms and sleep patterns in patients with fibromyalgia. J Rheumatol. 2003 May;30(5):1070–1074. [PubMed: 12734908]

Distler O, Eich W, Dokoupilova E, et al. Evaluation of the efficacy and safety of terguride in patients with fibromyalgia syndrome: results of a twelve-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 2010 Jan;62(1):291–300. [PubMed: 20039417]

Bennett RM, Kamin M, Karim R, Rosenthal N. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. Am J Med. 2003 May;114(7):537–545. [PubMed: 12753877]

Bennett RM, Schein J, Kosinski MR, Hewitt DJ, Jordan DM, Rosenthal NR. Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis Rheum. 2005 Aug 15;53(4):519–527. [PubMed: 16082646]

Russell J, Kamin M, Bennett RM, Schnitzer TJ, Green JA, Katz WA. Efficacy of tramadol in treatment of pain in fibromyalgia. JCR: Journal of Clinical Rheumatology. 2000;6(5):250–257. [PubMed: 19078481]

Moldofsky H, Lue FA, Mously C, Roth-Schechter B, Reynolds WJ. The effect of zolpidem in patients with fibromyalgia: a dose ranging, double blind, placebo controlled, modified crossover study. J Rheumatol. 1996 Mar;23(3):529–533. [PubMed: 8832997]

Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990 Feb;33(2):160–172. [PubMed: 2306288]

Center for Reviews and Dissemination. Undertaking systematic reviews of research on effectiveness: CRD’s guidance for those carrying out or commissioning reviews. CRD Report Number 4. 2nd ed. York, UK: NHS Centre for Reviews and Dissemination; 2001.

Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med. 2001 Apr;20(3 Suppl):21–35. [PubMed: 11306229]

Owens DK, Lohr KN, Atkins D. Grading the strength of a body of evidence when comparing medical interventions, Agency for Healthcare Research and Quality Methods Guide for Comparative Effectiveness Reviews. Rockville, MD: 2009. [PubMed: 21433399]

Owens DK, Lohr KN, Atkins D, et al. Grading the strength of a body of evidence when comparing medical interventions-Agency for Healthcare Research and Quality and the Effective Health Care Program. J Clin Epidemiol. 2010;63(5):513–523. [PubMed: 19595577]

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clinical Trials. 1986;7(3):177–188. [PubMed: 3802833]

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560. [PMC free article: PMC192859] [PubMed: 12958120]

Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–1558. [PubMed: 12111919]

Bennett RM, Gatter RA, Campbell SM, Andrews RP, Clark SR, Scarola JA. A comparison of cyclobenzaprine and placebo in the management of fibrositis. A double-blind controlled study. Arthritis Rheum. 1988 Dec;31(12):1535–1542. [PubMed: 3058130]

Carette S, McCain GA, Bell DA, Fam AG. Evaluation of amitriptyline in primary fibrositis. A double-blind, placebo-controlled study. Arthritis Rheum. 1986 May;29(5):655–659. [PubMed: 3521612]

Quimby LG, Gratwick GM, Whitney CD, Block SR. A randomized trial of cyclobenzaprine for the treatment of fibromyalgia. Journal of Rheumatology - Supplement. 1989 Nov;19:140–143. [PubMed: 2481741]

Reynolds WJ, Moldofsky H, Saskin P, Lue FA. The effects of cyclobenzaprine on sleep physiology and symptoms in patients with fibromyalgia. J Rheumatol. 1991 Mar;18(3):452–454. [PubMed: 1856814]

Scudds RA, McCain GA, Rollman GB, Harth M. Improvements in pain responsiveness in patients with fibrositis after successful treatment with amitriptyline. Journal of Rheumatology - Supplement. 1989 Nov;19:98–103. [PubMed: 2481743]

Carette S, Bell MJ, Reynolds WJ, et al. Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia. A randomized, double-blind clinical trial. Arthritis Rheum. 1994 Jan;37(1):32–40. [PubMed: 8129762]

Goldenberg D, Mayskiy M, Mossey C, Ruthazer R, Schmid C. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum. 1996 Nov;39(11):1852–1859. [PubMed: 8912507]

Heymann RE, Helfenstein M, Feldman D. A double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia. An analysis of outcome measures. Clin Exp Rheumatol. 2001 11-12;19(6):697–702. [PubMed: 11791642]

Ataoglu S, Ataoglu A, Erdogan F, Sarac J. Comparison of paroxetine, amitriptyline in the treatment of fibromyalgia. Turk J Med Sci. 1997;27:535–539.

Carville SF, Arendt-Nielsen S, Bliddal H, et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis. 2008 Apr;67(4):536–541. [PubMed: 17644548]

Hauser W, Bernardy K, Uceyler N, Sommer C. Treatment of fibromyalgia syndrome with gabapentin and pregabalin: a meta-analysis of randomized controlled trials (Provisional abstract). Pain. 2009;145(1–2):69–81. [PubMed: 19539427]

Hauser W, Petzke F, Sommer C. Comparative Efficacy and Harms of Duloxetine, Milnacipran, and Pregabalin in Fibromyalgia Syndrome. J. Pain. 2010;11(6):505–521. [PubMed: 20418173]

Nishishinya B, Urrutia G, Walitt B, et al. Amitriptyline in the treatment of fibromyalgia: a systematic review of its efficacy, Rheumatology (Oxford). 12. Vol. 47. Dec, 2008. pp. 1741–1746. [PubMed: 18697829]

Uceyler N, Hauser W, Sommer C. A systematic review on the effectiveness of treatment with antidepressants in fibromyalgia syndrome. Arthritis Rheum. 2008 Sep 15;59(9):1279–1298. [PubMed: 18759260]

Arnold L, Gendreau R, Palmer R, Gendreau J, Wang Y. Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62(9):2745–2756. [PubMed: 20496365]

Branco JC, Zachrisson O, Perrot S, Mainguy Y. Multinational Coordinator Study G. A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia. J Rheumatol. 2010 Apr;37(4):851–859. [PubMed: 20156949]

Carette S, Oakson G, Guimont C, Steriade M. Sleep electroencephalography and the clinical response to amitriptyline in patients with fibromyalgia. Arthritis Rheum. 1995 Sep;38(9):1211–1217. [PubMed: 7575714]

Ginsberg F, Mancaux A, Joos E, Vanhove P, Famaey JP. A randomized placebo-controlled trial of sustained-release amitriptyline in primary fibromyalgia. Journal of Musculoskeletal Pain. 1996;4(3):37–47.

Hannonen P, Malminiemi K, Yli-Kerttula U, Isomeri R, Roponen P. A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder. Br J Rheumatol. 1998 Dec;37(12):1279–1286. [PubMed: 9973149]

Arnold LM, Russell IJ, Diri EW, et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. Journal of Pain. 2008 Sep;9(9):792–805. [PubMed: 18524684]

Crofford LJ, Rowbotham MC, Mease PJ, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005 Apr;52(4):1264–1273. [PubMed: 15818684]

Mease PJ, Russell IJ, Arnold LM, et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol. 2008 Mar;35(3):502–514. [PubMed: 18278830]

Pfizer. A 14-Week, Randomized, Double-Blind, Placebo-Controlled Trial of Pregabalin Twice Daily in Patients with Fibromyalgia, Protocol A0081100. 2008. PhRMA Web Synopsis: Lyrica/Pregabalin (Unpublished Study)

Clauw DJ, Mease P, Palmer RH, Gendreau RM, Wang Y. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial.[Erratum appears in Clin Ther. 2009 Jul;31(7):1617].[Erratum appears in Clin Ther. 2009 Feb;31(2):446] Clin Ther. 2008 Nov;30(11):1988–2004. [PubMed: 19108787]

Gendreau RM, Thorn MD, Gendreau JF, et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol. 2005 Oct;32(10):1975–1985. [PubMed: 16206355]

Mease PJ, Clauw DJ, Gendreau RM, et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial.[Erratum appears in J Rheumatol. 2009 Mar;36(3):661] J Rheumatol. 2009 Feb;36(2):398–409. [PubMed: 19132781]

Vitton O, Gendreau M, Gendreau J, Kranzler J, Rao SG. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Human Psychopharmacology. 2004 Oct;19( Suppl 1):S27–35. [PubMed: 15378666]

Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 2004 Sep;50(9):2974–2984. [PubMed: 15457467]

Arnold LM, Rosen A, Pritchett YL, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain. 2005 Dec 15;119(1–3):5–15. [PubMed: 16298061]

Chappell AS, Bradley LA, Wiltse C, Detke MJ, D’Souza DN, Spaeth M. A six-month double blind placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. international Journal of General Medicine. 2008;1:91–102. [PMC free article: PMC2840539] [PubMed: 20428412]

Hunter AM, Leuchter AF, Cook IA, et al. Brain functional changes and duloxetine treatment response in fibromyalgia: a pilot study. Pain Medicine. 2009 05-06;10(4):730–738. [PubMed: 19453962]

Russell IJ, Mease PJ, Smith TR, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain. 2008 Jun;136(3):432–444. [PubMed: 18395345]

Straub TA. Endoscopic carpal tunnel release: a prospective analysis of factors associated with unsatisfactory results. Arthroscopy. 1999 Apr;15(3):269–274. [PubMed: 10231104]

Crofford LJ, Mease PJ, Simpson SL, et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain. 2008 Jun;136(3):419–431. [PubMed: 18400400]

Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults [Systematic Review] Cochrane Database of Systematic Reviews. 2009;1 [PMC free article: PMC4167351] [PubMed: 19588419]

Goldenberg DL, Felson DT, Dinerman H. A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheum. 1986 Nov;29(11):1371–1377. [PubMed: 3535811]

Straube S, Derry S, Moore RA, McQuay HJ. Pregabalin in fibromyalgia: meta-analysis of efficacy and safety from company clinical trial reports. Rheumatology (Oxford). 2010;49:706–715. [PubMed: 20056767]

Arnold L, Clauw D, Wohlreich M, et al. Efficacy of duloxetine in patients with fibromyalgia: pooled analysis of four placebo-controlled clinical trials. Prim Care Companion. J Clin Psychiatry. 2009;11(5):237–244. [PMC free article: PMC2781036] [PubMed: 19956462]

Bennett R. The Fibromyalgia Impact Questionnaire (FIQ): a review of its development, current version, operating characteristics and uses. Clin Exp Rheumatol. 2005;23(Suppl 39):S154–S162. [PubMed: 16273800]

Bennett RM, Bushmakin AG, Cappelleri JC, Zlateva G, Sadosky AB. Minimal clinically important difference in the fibromyalgia impact questionnaire. J Rheumatol. 2009;36(6):1304–1311. [PubMed: 19369473]

Arnold LM, Goldenberg DL, Stanford SB, et al. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum. 2007 Apr;56(4):1336–1344. [PubMed: 17393438]

Anderberg UM, Marteinsdottir I, von Knorring L. Citalopram in patients with fibromyalgia--a randomized, double-blind, placebo-controlled study. European Journal of Pain: Ejp. 2000;4(1):27–35. [PubMed: 10833553]

Norregaard J, Volkmann H, Danneskiold-Samsoe B. A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain. 1995 Jun;61(3):445–449. [PubMed: 7478688]

Arnold LM, Hess EV, Hudson JI, Welge JA, Berno SE, Keck PE Jr. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med. 2002 Feb 15;112(3):191–197. [PubMed: 11893345]

Wolfe F, Cathey MA, Hawley DJ. A double-blind placebo controlled trial of fluoxetine in fibromyalgia. Scand J Rheumatol. 1994;23(5):255–259. [PubMed: 7973479]

Giordano N, Geraci S, Santacroce C, Mattii G, Battisti E, Gennari C. Efficacy and tolerability of paroxetine in patients with fibromyalgia syndrome: A single-blind study. Curr Ther Res Clin Exp. 1999;60(12):696–702.

Patkar AA, Masand PS, Krulewicz S, et al. A randomized, controlled, trial of controlled release paroxetine in fibromyalgia. Am J Med. 2007 May;120(5):448–454. [PubMed: 17466657]

Hauser W, Thieme K, Turk DC. Guidelines on the management of fibromyalgia syndrome - a systematic review. European Journal of Pain: Ejp. 2010 Jan;14(1):5–10. [PubMed: 19264521]

Arnold BS, Alpers GW, Suss H, et al. Affective pain modulation in fibromyalgia, somatoform pain disorder, back pain, and healthy controls. European Journal of Pain: Ejp. 2008 Apr;12(3):329–338. [PubMed: 17723312]

Arnold LM, Crofford LJ, Martin SA, Young JP, Sharma U. The effect of anxiety and depression on improvements in pain in a randomized, controlled trial of pregabalin for treatment of fibromyalgia. Pain Medicine. 2007 11-12;8(8):633–638. [PubMed: 18028041]

Pae C-U, Masand PS, Marks DM, et al. History of depressive and/or anxiety disorders as a predictor of treatment response: a post hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release in patients with fibromyalgia. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Aug 31;33(6):996–1002. [PubMed: 19433129]

Emir B, Murphy TK, Petersel DL, Whalen E. Treatment response to pregabalin in fibromyalgia pain: effect of patient baseline characteristics. Expert Opin. Pharmacother. 2010;11(14):2275–2280. [PubMed: 20812879]